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Objectives: The incidence and the prevalence of eosinophilic esophagitis (EoE) are
increasing, and healthcare utilization among children with EoE is high. This study provides
novel insights into the health services and the treatments, including complementary
medicines (CMs), used by carers to manage their children’s EoE as well as the carers’
beliefs and attitudes toward these treatments.
Methods: A national cross-sectional online survey was conducted in Australia between
September 2018 and February 2019. The survey included questions about health service
and treatment utilization, health insurance and government support, health-related quality
of life of children with EoE and their carers, views and attitudes toward CM use, and
perceived efficacy of treatment.
Results: The survey was completed by 181 carers (96.6% of whom were mothers) of
EoE children. Most children (91.2%, n = 165) had seen a medical doctor for their EoE,
and almost half had consulted with a CM practitioner (40.3%, n = 73). Pharmaceuticals
(n = 156, 86.2%) were the most commonly used treatment option, followed by dietary
changes (n = 142, 78.5%), CM products (n = 109, 60.2%), and CM therapies (n = 42,
23.2%). Most children received care from numerous practitioners on multiple occasions,
indicating a substantial financial and treatment-related burden.
Conclusions: A variety of practitioners are involved in the care of children with EoE, and
a high rate of CM use warrants further attention to ensure that appropriate treatment
is provided. Carer involvement and guidance, combined with individual practitioner
expertise, referrals, and collaboration between providers, is essential to successfully
navigate this complex disease and provide adequate care for these patients.
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INTRODUCTION
Eosinophilic esophagitis (EoE) is a rare antigen-driven
inflammatory gastrointestinal disorder characterized by elevated
levels of eosinophils in the esophagus, esophageal dysfunction,
and gastrointestinal symptoms (1). EoE incidence is increasing
globally, with an estimated prevalence of one in every 2,000
people (2–4). International clinical guidelines list EoE first-line
treatment options as proton-pump inhibitors, swallowed topical
steroids, elimination diets, and elemental formula (5–8). While
there are no national guidelines in Australia for the management
of EoE, international guidelines are usually applied (9).
Given the high frequency of healthcare utilization among
children with EoE (10), it is important to better understand
the patterns of use in order to improve the support for these
children and their carers as well as facilitate more coordinated
and collaborative care between healthcare providers. Research
suggests that complementary medicine (CM), a diverse range
of medical and healthcare practices and products not currently
regarded as part of conventional medicine (11), may be included
in the range of healthcare accessed by carers of children
diagnosed with gastroenterological conditions in Australia (12)
and abroad (13). In order to address EoE symptoms, carers may
choose CMs for their children, under the assumption that CMs
are safe (14, 15); however, to our knowledge, no research has
examined all healthcare accessed for pediatric EoE, including
CM. In response, this study is the first to describe the health
services and the treatments, including CMs, used by carers to
manage their children’s EoE as well as the carers’ beliefs and
attitudes toward these treatments.
METHODS
Definitions
CM involves two broad classifications, defined in this study
as either CM products (i.e., probiotics) or CM therapies (i.e.,
massage) (11).
Study Design and Setting
A national cross-sectional online survey was conducted between
September 2018 and February 2019. Ethics approval was
obtained from the Griffith University Human Research Ethics
Committee (#2018/120). The survey included the following
domains: demographics; health service and treatment utilization;
health insurance, government support, and rebates; health-
related quality of life (HRQoL) of children with EoE and their
carers; views and attitudes toward CM use; and perceived efficacy
of treatment.
Survey Design
The survey instrument was designed to take 20–30min to
complete and incorporated pre-existing validated tools, namely,
Bakas Caregiving Outcomes Scale© (16), PedsQLTM Eosinophilic
Esophagitis Module Standard Version 3.0 Parent Reports©
(17), and PedsQLTM Infant Scales© (18), along with other
adapted survey items (see Table 1). In addition to the pre-
existing instruments, the survey items were drafted to confirm
eligibility [mandatory questions included: “Did your child have
an endoscopy to assist with EoE diagnosis?” and “Has your child
been diagnosed with EoE by a pediatric gastroenterologist (or
other medical specialist)?”], ensure that the questions addressed
the CM use in children, not the carer, and gauge treatment
burden [the workload attributed to healthcare, and its impact
on patient well-being and functioning (38)], and access to
funding support for EoE patients. This included questions about
access to private health insurance and a government-issued
healthcare card and/or carer allowance. Australia’s public health
system provides access to a wide range of hospital and health
services for all Australians at low or no cost (39). In Australia,
additional private health insurance can be purchased to cover
specific costs related to private hospital treatment and other
medical services (40). Carer allowance is means tested and is
available for those persons who provide additional daily care
to a child who has a serious chronic illness (41). Healthcare
cards can reduce the cost of certain prescription medications
and medical doctor consultations and are issued to persons
receiving various government payments or subsidies, including
carer allowance (42).
The survey was tested for content and face validity, with
feedback obtained by two parents of childrenwith chronic disease
using a paper version of the survey, followed by online testing
via the Survey Gizmo R© platform by the parent of a child with
eosinophilic gastroenteritis. The lead researcher and the parent of
a child with EoE also tested the online version on different devices
(e.g., tablet, phone, and laptop). Minor changes to improve
readability and understanding were made based on the feedback
from the different parties and following discussions among the
research team.
Participants
The study participants were English-speaking carers of children
with a confirmed EoE diagnosis (≤18 years of age) in Australia.
The target survey sample size of 210 parents of EoE children was
determined to achieve a 95% confidence level, confidence interval
of 5, and population of 462 from a prevalence rate of 1 in 10,000
(2, 43).
Recruitment
Purposive convenience and snowball sampling were employed.
The responses were limited to one survey per family; if more than
one child in the family had EoE, the respondents were asked to
complete the survey for the eldest child only.
The Australian pediatric EoE support network, AusEE Inc.,
promoted the survey to their network of consumer members,
their medical advisory board, other specialist doctors, and
organizations such as Allergy and Anaphylaxis Australia
and Allergy and Immunology Foundation of Australasia.
Professional associations—the Australasian Society of Clinical
Immunology and Allergy, the Gastroenterological Society of
Australia, Australian Society of Pediatric Gastroenterology
Hepatology and Nutrition, and the Royal Australian College
of General Practitioners—invited their members to assist with
the recruitment. The research team also directly contacted
specialized EoE clinicians, general practitioners (GPs),
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TABLE 1 | Validated tools incorporated in the survey instrument.
Validated tool Measures
Bakas Caregiving Outcomes Scale© Bakas (2007)* (16) Life changes in family caregivers. Validated for use in caregivers
PedsQLTM Eosinophilic Esophagitis Module Standard Version 3.0
Parent reports© Varni (2012)* (17)
Parents’ perceptions of the HRQoL of their EoE child in the previous month. Validated for use in
pediatric EoE for children aged 2–18 years old
PedsQLTM Infant Scales© Varni (1998)* (18) HRQoL. Validated for use in healthy and ill infants aged 0–24 months
Australian Bureau of Statistics 2016 Census Household Form# (19) Age, ethnicity, and language spoken at home. Validated for use in the Australian general population
PedsQLTM Family Information Form© Varni (1998)# (20) Demographic details including the child’s date of birth and gender and the impact of EoE on
hospital visits, school absences, and parental work absences. Validated for use in pediatric
patients with chronic disease
Complementary Medicine Use, Literacy and Disclosure in the
Australian Population# (21, 22)
Patterns of CM use; understanding and communication of CM use. Validated for use in the
Australian general population
Complementary Therapies Questionnaire# (12) Experiences and perceptions of CM use including concerns, reasons for use, views on future use,
decisions leading to use, and perceived efficacy of CM treatment. Validated for use in pediatric
inflammatory bowel disease patients
*Minor amendments were made, including spelling and grammatical changes, to ensure that they were appropriate for an Australian audience and were specific to EoE populations.
#Specific survey items have also been adopted from other pre-existing validated tools to confirm sociodemographic details (19, 20), patterns of CM use, understanding and
communication of CM use patterns (21, 22), and experiences and perceptions of CM use including concerns, reasons for use, views on future use, decisions leading to use, and
perceived efficacy of CM treatment (12).
Additional survey items were developed from literature reporting CM and other health service use in chronic inflammatory pediatric diseases, including gastrointestinal disorders
(12, 13, 17, 23–37), to confirm eligibility, ensure that that the questions addressed CM use in children not the career, gauge treatment burden [the workload attributed to healthcare and
its impact on patient well-being and functioning (38)], and access funding support for EoE patients.
and hospital-based pediatric allergy and gastroenterology
departments across Australia and invited their assistance with
recruitment. Snowball sampling was used to encourage medical
specialists and carers of pediatric EoE children to ask others to
participate. The survey incorporated a participant information
sheet and a consent statement, with consent implied by survey
completion. The participants had the opportunity to win one of
10 AU$50 gift vouchers (via two prize draws of five vouchers
each) upon survey completion.
Data Collection
Demographic Characteristics
Child age, age at diagnosis, gender, ethnicity, residential
postcode, health cover, and carer allowance details were obtained,
as well as carer gender and their relationship to the EoE child.
Health Service and Treatment Utilization
The participants were asked to provide information regarding
the health services and treatment used by their EoE child,
including the recommendation source of each health service
and treatment and the frequency of practitioner consultations
and associated out-of-pocket expenditure in the previous 12
months. Medicine use, treatments, and practices were separated
into pharmaceuticals, CM products, CM therapies, and dietary
changes. In accordance with schedule 14 of the Australian
Government Therapeutic Goods Regulations 1990, CM products
were defined according to their active ingredient, e.g., “a vitamin
or provitamin,” not by the purpose of usage, i.e., a vitamin
deficiency (44).
Data Analysis
Descriptive statistics were determined for each variable.
STATA/IC 15 statistical analysis software was used for the data
analysis. Missing answers for questions where the respondents
were asked to indicate agreement and no other option was
provided were classified as “no.” All other instances where
an answer was not provided were excluded from the analysis.
Potential overlap of practitioner type was identified through the
participants who provided examples of one practitioner with
multiple qualifications, including allergist/immunologist (n =
3), dietitian/nutritionist (n = 1), and naturopath/nutritionist
(n = 1). As there was no way to determine if multiple answers
were selected for the same practitioner for all respondents,
original values were retained. “Other” open-text responses
in all categories were reviewed and amendments were made
accordingly. For example, where not already allocated to another
practitioner, “undergoing hypnotherapy” was allocated to a
hypnotherapist, and “once” was reclassified as one to two visits
to a practitioner. Where the respondents provided “Other”
recommendation sources for child medicines, products, and
therapies, that were among the listed options of specified
practitioners, the “Other” response was re-classified to the
listed category. Where gastroenterologist was listed as “Other,”
the response was amended to pediatric gastroenterologist. The
frequency of visit percentages was calculated from individual “use
ever” totals for each health practitioner type. Only respondents
who indicated that the use of the medicine, product, and therapy
type was for their child’s EoE were included in the data analysis.
A new variable was also created to represent the total number
of practitioner types visited, excluding visits with a “pharmacy
or health food store assistant” as this role does not require
defined professional or clinical training. Poisson regression
analysis was used to determine the relationship between ‘time
since diagnosis’ and use of treatments that have been strongly
recommended against (in this study, mast cell stabilizers and
antihistamines) (5). Logistic regression analysis was used to
determine if private health insurance status was a predictor of
CM use for pediatric EoE.
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RESULTS
A total of 181 survey responses were included in the analysis after
the incomplete survey responses were removed.
Demographics
A total of 232 survey responses were received. Thirty-five
incomplete responses were removed, as well as those that did not
meet the inclusion criteria (n = 16). These included responses
with no confirmed EoE diagnosis (n = 12), residence outside
of Australia (n = 1), completion by an EoE child instead
of their parent (n = 2), and child whose age is over 18
years (n = 1). The remaining 181 responses were used for
data analysis.
Carer and EoE Child Characteristics
The surveys were almost exclusively completed by a parent (n
= 178)—in most cases, the mother (n = 173) of the EoE child
(see Table 2). The children were identified predominantly as
White/Caucasian (93.3%) and males (71.7%), ages between 13
months and 18 years were represented (mean 9.70; SD 4.67), and
the mean time since diagnosis for this study was 4.13 years (SD
3.38; min 0; max 14.17). Most children were covered by a private
health insurance (63.3%), but <1/2 of the families received
additional financial support from the Australian Government to
reduce out-of-pocket medical expenses through a healthcare card
(39.4%) or financial support through a carer allowance (27.8%).
Private health insurance status was not found to be a significant
predictor of overall CM use (practitioner, product, or therapy)
for pediatric EoE (p = 0.86, OR 1.06; 95% CI: 0.54–2.09), CM
practitioner use only (p = 0.19, OR 1.54; 95% CI: 0.81–2.94),
or CM product or therapy use only (p = 0.92, OR 0.97; 95%
CI: 0.51–1.85).
Health Service Use
Most children (88.4%) received care from three or more
different types of practitioner, with almost two-thirds (60.8%)
consulting six or more practitioner types for their EoE. Most
children (91.2%) had consulted a medical doctor for their
EoE. The most commonly accessed healthcare practitioners at
any time for EoE were a pediatric gastroenterologist (86.2%),
GP (84.5%), allergist (70.2%), and dietitian (69.6%) (reported
in Table 3). Almost half of the respondents had consulted
a CM practitioner (40.3%) at some time-point after their
child’s diagnosis, with a naturopath (22.1%) being the most
commonly accessed. Most respondents indicated that they saw
any type of medical doctor once or twice in the last 12
months. GPs were mostly visited, with more than six visits
in the past 12 months (27.0%). Although we are unable to
determine if multiple practitioner use was simultaneous or
sequential in the previous 12 months, the mean number of
different types of practitioner seen for a child’s EoE was 4.6
(SD 2.99; min 0; max 12); one-fifth (20.7%) of the respondents
indicated that their child had seen both a medical doctor and a
CM practitioner.
Use and Perceived Effectiveness of
Pharmaceuticals, CMs, and Dietary
Changes
Pharmaceuticals (86.2%) were the most commonly used
treatment option at any time for pediatric EoE, followed by
dietary changes (78.5%), CMproducts (60.2%), and CM therapies
(23.2%) (see Table 4). Most respondents indicated that reflux
medications (77.9%) had been used for EoE management.
Probiotics (43.1%) and nutritional supplements (40.9%) were the
most used CM products. Dietary changes were common, with
over three quarters (75.1%) of all respondents indicating that they
had used elimination diets in the management of their child’s
EoE, followed by elemental formula (43.7%).
Amongst the pharmaceuticals listed, most respondents
(74.4%) perceived corticosteroids as effective, followed by mast
cell stabilizers (68.5%). The mast cell stabilizers (n = 23) also
had the highest percentage (10.5%) of “made worse” responses,
over four times greater than each of the other pharmaceuticals.
Poisson regression analysis determined that the risk of children
using treatments strongly recommended against in EoE therapy,
namely, mast cell stabilizers and antihistamines, is 1.6 times
greater (CI 1.0–2.6, p = 0.05) between 2 and 4 years since
diagnosis and 1.9 times greater (CI 1.2–2.9, p = 0.003) at 4
years or more after diagnosis when compared with children
in their first 2 years since diagnosis. Almost one quarter of
the respondents perceived reflux medications (n = 31) to be
ineffective in EoE management. Despite the small sample sizes
for most CM products, the respondents reported high levels
of perceived effectiveness for Chinese herbal medicines (n =
3, 75.0%) and Western herbal medicines (n = 5, 71.4%).
Acupuncture was more often perceived to be ineffective (n =
2; 33.3%) than effective (n = 1; 16.7%). No CM therapy was
perceived to have made the child’s EoE worse. While most
respondents felt that elemental formula was effective (71.2%), 14
respondents found it ineffective and seven were uncertain. The
overall effectiveness of the elimination diet (76.2%) was slightly
higher than that of the elemental formula.
Sources of Recommendation
All pharmaceuticals used for EoE treatment were predominantly
recommended by medical doctors (Table 5). Corticosteroids
were recommended by a pediatric gastroenterologist in over
80% of cases, as were reflux medications (87.9%). Mast
cell stabilizers were only recommended by immunologists,
pediatric gastroenterologists, and allergists. All CM therapies
were predominantly self-prescribed by the carer (Table 5).
Medical doctors and other non-CM practitioners were more
likely to recommend nutritional supplements and probiotics
than any other type of CM. Dietitians recommended nutritional
supplements in over 40% of cases, while only 28.4% (n = 21)
were recommended by pediatric gastroenterologists and 24.3%
(n = 18) were recommended by CM practitioners. Probiotics
were equally recommended by CM practitioners (25.6%) or
self-prescribed (25.6%). Elimination diet (69.9%) and elemental
formula (62.0%) were mostly recommended by pediatric
gastroenterologists, followed by allergists (elimination diet:
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TABLE 2 | Sociodemographic characteristics of carers and of EoE children as reported by carers.
Child’s characteristics n (%) Carer characteristics n (%)
Child’s gender (n = 180) Carer gender (n = 180)
Male 129 (71.7) Male 5 (2.8)
Female 51 (28.3) Female 175 (97.2)
Child’s age# (n = 180) Carer relationship to child (n = 179)
1–23 months 4 (2.2) Mother 173 (96.6)
2–4 years 22 (12.2) Father 5 (2.8)
5–7 years 35 (19.4) Grandmother 1 (0.6)
8–12 years 69 (38.3) Carer state of residence (n = 179)
13–18 years 50 (27.8) Australian Capital Territory 4 (2.2)
Child’s age at diagnosis (n = 181) New South Wales 61 (34.1)
1–23 months 45 (24.9) Northern Territory 1 (0.6)
2–4 years 46 (25.4) Queensland 46 (25.7)
5–7 years 34 (18.8) South Australia 14 (7.8)
8–12 years 45 (24.9) Tasmania 0 (0.0)
13–18 years 11 (6.1) Victoria 31 (17.3)
Time since diagnosis (n = 180) SD; min–max Western Australia 22(12.3)
Mean 4.13 years 3.38; 0–14.17 Applied for and approved carer allowance (n = 180)
Child’s ethnicity (n = 180) n (%) Yes 50 (27.8)
White/Caucasian 168 (93.3) No 130 (72.2)
Aboriginal/Torres strait islander 1 (0.6)
Asian 4 (2.2)
Middle eastern 2 (1.1)
Other 5 (2.8)
Current healthcare card (n = 180)
Yes 71 (39.4)
No 109 (60.6)




#Child’s age at survey completion.
34.6%, elemental formula: 31.7%) and dieticians (elimination
diet: 30.2%, elemental formula: 29.1%). Some patients who had
used an elimination diet had never seen a dietician or nutritionist
(15.4%). Almost one-third of carers self-prescribed (29.4%, n =
47/160) non-prescription only pharmaceuticals, CMs, or dietary
changes for their EoE child.
DISCUSSION
To our knowledge, this is the first study to explore health service,
medicine, and CM use for pediatric EoE. It is difficult to estimate
the percentage of the pediatric EoE population in Australia that
was captured by this survey as the prevalence rates are changing
rapidly (43). The survey was designed in 2017 and undertaken
between September 2018 and March 2019. During this time, the
prevalence data, based on international (4, 45) and Australian
(43) studies, ranged from 1 to 5 in 10,000 and may be as high
as 1 in 1,000 in 2020 (2). According to Australian census data
(46), it would mean that the survey captured between 4 and 40%
of the pediatric EoE population in Australia, depending on what
would be considered as accurate prevalence data at the time. A
2018 systematic review andmeta-analysis (47), which included 13
studies, focused on HRQoL in patients with EoE of all ages. The
sample sizes ranged from n= 8 (Australia) (48) to n= 140 (USA)
(49), emphasizing the large sample size of the study reported here.
The EoE children in our study were identified predominantly
as White/Caucasian (93.3%) and of male gender (71.7%), which
is representative of the general pediatric EoE population (50).
The representation by children of all ages (between 13 months
to 18 years) and the broad range of time since diagnosis indicate
that the responses represented patients at varied stages in their
EoE management.
Our study showed that most (86.2%) children had been
given a pharmaceutical at some stage to treat their EoE. Reflux
medications such as proton pump inhibitors are a first-line
treatment option for EoE (7) and were the most commonly
used pharmaceutical. However, proton pump inhibitors may be
associated with adverse side effects when used for a long term
(51), and almost one quarter of those respondents who had used
Frontiers in Pediatrics | www.frontiersin.org 5 April 2020 | Volume 8 | Article 147
Hannan et al. Pediatric EoE Health Service Use
TABLE 3 | Prevalence and frequency of health service use by EoE children (n = 181).
Practitioner type Use ever
n (%)#
Frequency of visits in the past 12 months n (%)
None 1–2 3–4 5–6 More than 6
n (%) n (%) n (%) n (%) n (%)
MEDICAL DOCTORS
Allergist 127 (70.2) 31 (25.4) 69 (56.5) 14 (11.5) 5 (4.1) 3 (2.5)
General practitioner 153 (84.5) 20 (13.5) 44 (29.7) 31 (21.0) 13 (8.8) 40 (27.0)
Hospital doctor 99 (54.7) 28 (29.8) 30 (31.9) 15 (16.0) 13 (13.8) 8 (8.5)
Immunologist 90 (49.7) 19 (22.9) 47 (56.6) 10 (12.1) 5 (6.0) 2 (2.4)
Pediatric gastroenterologist 156 (86.2) 9 (6.1) 55 (37.2) 45 (30.4) 32 (21.6) 7 (4.7)
Pediatrician 96 (53.0) 34 (37.4) 42 (46.1) 9 (9.9) 4 (4.4) 2 (2.2)
CM PRACTITIONERS
Acupuncturist 7 (3.9) 5 (71.4) 1 (14.3) 1 (14.3) 0 (0.0) 0 (0.0)
Aromatherapist 3 (1.7) 1 (33.4) 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0)
Chiropractor 31 (17.1) 13 (46.4) 4 (14.3) 7 (25.0) 0 (0.0) 4 (14.3)
Homeopath 11 (6.1) 5 (50.0) 1 (10.0) 3 (30.0) 1 (10.0) 0 (0.0)
Massage therapist 8 (4.4) 2 (28.6) 2 (28.6) 1 (14.2) 2 (28.6) 0 (0.0)
Naturopath 40 (22.1) 17 (46.0) 11 (29.7) 4 (10.8) 0 (0.0) 5 (13.5)
Osteopath 8 (4.4) 6 (85.7) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0)
Relaxation/meditation teacher 7 (3.9) 2 (33.3) 4 (66.7) 0 (0.0) 0 (0.0) 0 (0.0)
Tai chi or qigong teacher 1 (0.6) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Traditional Chinese medicine practitioner 1 (0.6) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Western herbalist 4 (2.2) 3 (75.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0)
Yoga teacher 4 (2.2) 0 (0.0) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0)
OTHER HEALTH PRACTITIONERS OR HEALTH WORKERS
Counselor or other mental health worker 45 (24.9) 10 (23.8) 11 (26.2) 3 (7.1) 7 (16.7) 11 (26.2)
Dietitian 126 (69.6) 44 (36.7) 39 (32.5) 22 (18.3) 9 (7.5) 6 (5.0)
Nutritionist 41 (22.7) 17 (47.2) 12 (33.3) 2 (5.6) 1 (2.8) 4 (11.1)
Pharmacist 74 (40.9) 7 (10.0) 15 (21.4) 11 (15.7) 10 (14.3) 27 (38.6)
Pharmacy or health food store assistant 41 (22.7) 4 (10.5) 11 (28.9) 5 (13.2) 6 (15.8) 12 (31.6)
Other practitioner 20 (11.1) 2 (13.3) 3 (20.0) 2 (13.3) 1 (6.7) 7 (46.7)
#The total number of practitioners is greater than the number of responses as some respondents listed more than one other practitioner.
them perceived them to be ineffective in EoEmanagement, which
is in line with previous findings (52). Proton pump inhibitors
can reduce the absorption and bioavailability of nutrients, such
as calcium, iron, magnesium, and vitamin B12 (51), which are
particularly important in a pediatric population (53). Yet there
is limited information on the safety, benefits, and bioavailability
of different forms of nutrients, specifically for supplementation
in EoE. Mast cell stabilizers and antihistamines, although their
use is strongly recommended against for EoE treatment (5),
were perceived as effective by most responders. Yet 10.5% of
the respondents perceived mast cell stabilizers to have made
EoE symptoms worse, over four times greater than reported
for each of the other pharmaceuticals. This reflects the need
for qualitative interviews to further understand how efficacious
treatment is perceived by the parents of children with EoE and for
additional research to provide evidence-based treatment options
for these patients as well as improved practitioner awareness and
education regarding EoE treatment guidelines.
The reported CM use was high, with the respondents
indicating that they had consulted with a CM practitioner
(40.3%), used CM products (60.2%), or used CM therapies
(23.2%) tomanage their child’s EoE. Nutritional supplements and
probiotics were the CM products most commonly recommended
by a health professional for EoE, with medical doctors and
other non-CM practitioners being more likely to recommend
them than any other CM product. As CM products were
defined according to their active ingredient (e.g., “a vitamin
or provitamin”), not by the purpose of usage (e.g., to correct
a deficiency or to supplement in general), supplementation
with, e.g., vitamin D, calcium, or iron to correct deficiencies
is also counted as CM use. Anecdotally, the wait time for
consultations within the Australian public health system [all
costs are subsidized by the Australian Government for Australian
citizens (39)] for pediatric gastroenterologists and pediatric
allergy specialists (allergist/immunologist) can be 12–18 months.
Although the waitlists may be reduced for patients opting
to consult pediatric gastroenterologists in private practice,
out-of-pocket expenses can be higher, particularly for those
without a private health insurance cover. Long wait times
to access pediatric allergy and gastroenterology specialists
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TABLE 4 | Perceived effectiveness of pharmaceuticals, complementary medicines (CMs), and dietary changes for pediatric EoE (n = 181).
Medicines, treatments, and practices Use ever
n (%)
Perceived effectiveness n (%)
Very effective Partially effective Not effective Made worse Unsure
n (%) n (%) n (%) n (%) n (%)
PHARMACEUTICALS
Antihistamines 107 (59.1) 15 (15.5) 39 (40.2) 24 (24.7) 2 (2.1) 17 (17.5)
Corticosteroids 127 (70.2) 42 (35.9) 45 (38.5) 15 (12.8) 3 (2.6) 12 (10.2)
Mast cell stabilizers 23 (12.7) 8 (42.1) 5 (26.4) 2 (10.5) 2 (10.5) 2 (10.5)
Reflux medications 141 (77.9) 41 (30.8) 45 (33.8) 31 (23.3) 3 (2.3) 13 (9.8)
Other pharmaceuticals∧ 2 (1.2)
Any pharmaceuticals∧ 156 (86.2)
CM PRODUCTS
Chinese herbal medicines 4 (2.2) 0 (0.0) 3 (75.0) 0 (0.0) 1 (25.0) 0 (0.0)
Flower essences 14 (7.7) 1 (8.3) 1 (8.3) 5 (41.7) 0 (0.0) 5 (41.7)
Homeopathic medicines 16 (8.8) 0 (0.0) 6 (46.1) 4 (30.8) 2 (15.4) 1 (7.7)
Nutritional supplements 74 (40.9) 6 (9.1) 24 (36.4) 14 (21.2) 2 (3.0) 20 (30.3)
Probiotics 78 (43.1) 5 (7.3) 21 (30.4) 17 (24.6) 6 (8.7) 20 (29.0)
Western herbal medicines 7 (3.9) 2 (28.6) 3 (42.8) 2 (28.6) 0 (0.0) 0 (0.0)
Other complementary medicines∧ 3 (1.7)
Any complementary medicines∧ 109 (60.2)
CM THERAPIES
Acupuncture 6 (3.3) 0 (0.0) 1 (16.7) 2 (33.3) 0 (0.0) 3 (50.0)
Aromatherapy 18 (9.9) 1 (6.7) 6 (40.0) 3 (20.0) 0 (0.0) 5 (33.3)
Massage 12 (6.6) 0 (0.0) 4 (40.0) 4 (40.0) 0 (0.0) 2 (20.0)
Relaxation techniques/meditation 25 (13.8) 1 (4.8) 13 (61.9) 7 (33.3) 0 (0.0) 0 (0.0)
Yoga 5 (2.8) 0 (0.0) 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0)
Other complementary treatments∧ 6 (3.3)
Any complementary treatment∧ 42 (23.2)
DIETARY CHANGES
Elemental formula 79 (43.7) 34 (46.6) 18 (24.6) 14 (19.2) 0 (0.0) 7 (9.6)
Elimination diet 136 (75.1) 46 (36.5) 50 (39.7) 14 (11.1) 11 (8.7) 5 (4.0)
Other dietary changes∧ 2 (1.1)
Any dietary changes∧ 142 (78.5)
∧Perceived effectiveness not available as in some cases one option was chosen for multiple “other” medicines, treatments, and practices.
within the Australian public health system but easy access
to a CM practitioner and products may enhance CM use in
this population. Given that carers of children with chronic
inflammatory gastrointestinal disease expect the practitioners
to be knowledgeable about CM use (54), further research into
commonly used CMs for pediatric EoE and education are
required so that all practitioners involved in the care are enabled
to give evidence-based advice.
The participants in our study reported perceiving some
pharmaceuticals and CM products to lack efficacy or worsen
symptoms. While there may be several reasons for these results,
including worsening of symptoms due to the use of an ineffective
treatment, they warrant further investigation in consumer
interviews. Inadvertent exposure to an antigenic EoE or IgE
allergy trigger can occur due to the inadequate health literacy
of the carer, poorly executed elimination diet, or undisclosed
excipient ingredients in the medicine itself. For example,
otherwise effective medicines may be perceived as ineffective due
to containing unknown excipients such as milk proteins, soy,
wheat, corn, rice, and potato, which can be common EoE antigens
(55). Depending on therapeutic regulations, this information
may be omitted from product labeling (56, 57). It is therefore
vital to raise awareness and knowledge among clinicians and
self-prescribing carers of EoE children about medicine excipients
and engage the expertise of pharmacists or other stakeholders to
reduce the risk of exposure to known EoE triggers.
Our study also found that almost one-third of carers
self-prescribe non-prescription-only pharmaceuticals, CMs or
dietary changes for their EoE child. The importance of carers
in the management of pediatric EoE and the selection of
treatment options should not be underestimated. Consequently,
practitioners should facilitate open discussions with carers
regarding their complete medicine and treatment use for their
EoE child. With limited research into the efficacy and safety
of EoE treatment and management options, parent perceptions,
experiences, and decisions provide valuable insights (58), which





























TABLE 5 | Source of recommendation for pharmaceuticals, complementary medicines (CMs), and dietary changes for pediatric EoE (n = 181).
Pharmaceuticals, CMs,
and dietary changes




















n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
PHARMACEUTICALS
Antihistamines (n = 107) 54 (50.5) 29 (27.1) 24 (22.4) 12 (11.2) 32 (29.9) 8 (7.5) 4 (3.7) 2 (1.9) 0 (0.0) 1 (0.9) 0 (0.0) 3 (2.8) 4 (3.7)
Corticosteroids (n = 127) 22 (17.3) 13 (10.2) 102 (80.3) 7 (5.5) 7 (5.5) 6 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mast cell stabilizers (n = 23) 6 (26.1) 10 (43.5) 9 (39.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)




0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (75.0) 0 (0.0) 1 (25.0) 0 (0.0)
Flower essences (n = 14) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 1 (7.1) 1 (7.1) 0 (0.0) 5 (35.7) 0 (0.0) 1 (7.1) 8 (57.1)
Homeopathic medicines
(n = 16)
0 (0.0) 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 0 (0.0) 0 (0.0) 9(56.3) 0 (0.0) 2 (12.5) 2 (12.5)
Nutritional supplements
(n = 74)
10 (13.5) 6 (8.1) 21 (28.4) 4 (5.4) 10 (13.5) 1 (1.4) 2 (2.7) 33 (4.6) 0 (0.0) 18 (24.3) 1 (1.4) 1 (1.4) 10 (13.5)
Probiotics (n = 78) 7 (9.0) 6 (7.7) 11 (14.1) 3 (3.9) 15 (19.2) 0 (0.0) 4 (5.1) 17 (21.8) 0 (0.0) 20 (25.6) 2 (2.6) 2 (2.6) 20 (25.6)
Western herbal medicines
(n = 7)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 5 (71.4) 0 (0.0) 2 (28.6) 1 (14.3)
CM THERAPIES
Acupuncture (n = 6) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 4 (66.7)
Aromatherapy (n = 18) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (38.9) 1 (5.6) 3 (16.7) 6 (33.3)




1 (4.0) 0 (0.0) 1 (4.0) 1 (4.0) 2 (8.0) 1 (4.0) 0 (0.0) 0 (0.0) 7 (28.0) 2 (8.0) 0 (0.0) 0 (0.0) 11 (44.0)
Yoga (n = 5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (20.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0)
DIETARY CHANGES
Elemental formula (n = 79) 25 (31.7) 9 (11.4) 49 (62.0) 9 (11.4) 4 (5.1) 3 (3.8) 0 (0.0) 23 (29.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3)
Elimination diet (n = 136) 47 (34.6) 21 (15.4) 95 (69.9) 10 (7.4) 3 (2.2) 3 (2.2) 0 (0.0) 42 (30.9) 0 (0.0) 7 (5.2) 0 (0.0) 0 (0.0) 6 (4.4)
*Total sources of recommendation may be different than the number of users if the respondents selected more than one or no recommendation source.
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are worthy of increased attention. Parental proxy report in
young children with EoE can function as an adequate marker
for child self-reported symptoms and HRQoL measures (59).
Additionally, parent involvement in decision making has been
shown to improve a child’s treatment outcomes (60), suggesting
that carers play an important role in disease management
and should be seen as treatment partners by the practitioners.
However, due to the scarcity of evidence-based treatment options
in EoE, it is challenging for the practitioners to effectively fulfill
the carers’ and the patients’ expectations and needs.
Elimination diets were commonly used by study participants
and were mostly reported as being recommended by pediatric
gastroenterologists. Decisions surrounding the choice and the
implementation of dietary elimination and re-introduction are
complex and can result in treatment failure or symptom
worsening, potentially due to factors such as inadequate patient
education, non-adherence, and atypical individual triggers (61,
62). Unfortunately, at least one in seven respondents who
had used an elimination diet had never consulted a dietitian
or nutritionist. The reason may lay in the fact that neither
profession is classified as a registered health profession in
Australia (63), leading to a lack of clarity surrounding the
education, qualification, and professional standards of these
professions for consumers. As EoE is one of many diseases
requiring expert dietary management, it is imperative that these
professions are regulated through professional registration which
would result in the implementation of mandatory educational
and practice standards, leading to enhanced trust and acceptance
by consumers and therefore most likely to higher consultation
rates. There is evidence that gastroenterologists often agree to
patient-driven elimination diets without dietitian support and
do not adhere to the recommendations for repeated biopsies to
monitor ongoing response to therapy (64). This underutilization
of dietitians and nutritionists in our study may reflect a lack
of referral by gastroenterologists, allergists, and immunologists
or a scarcity of practitioners with specialized knowledge; hence,
identifying and accessing them may prove challenging for both
the referring practitioners and the carers. Given that elimination
diets are first-line treatment options in EoE and the high
percentage of EoE patients using them, it is paramount to
increase workforce education and educational resources and
encourage collaboration between all practitioners to establish
a wider referral network and provide specified support for
EoE patients.
The necessity of collaboration between practitioners and
the close communication with carers is particularly warranted
as most children received care from three or more different
practitioner types, with almost two-thirds having seen six or
more different types of practitioner for their EoE. This high
rate of diversity in practitioner types accessed for children with
EoE is congruent with existing data on healthcare utilization
by children with a rare disease (65). The parents of children
with a rare disease often feel isolated and under-supported and
perceive that there is poor coordination between care providers,
requiring the parent to fill multiple roles and become the “expert”
in the care of their child (65, 66). This social burden may be
amplified by the financial burden to carers. In Australia, private
health insurance can cover specific cost related to private hospital
treatment and other medical services, which could include
certain CMs (40). Our study shows that a higher percentage of
EoE patients (63.3%) have private health insurance than is seen in
the general Australian population (53.5%) (67). Carer allowance
is available for those persons who provide additional daily care
to a child who has a serious chronic illness (41). Healthcare
cards can reduce the cost of certain prescription medications
and medical doctor consultations and are automatically issued
to those persons receiving various government payments or
subsidies, including carer allowance (42). Our study showed
that nearly two-thirds of the children did not have a healthcare
card and a third of the respondents did not have private health
insurance to reduce out-of-pocket expenses. Further exploration
of financial burden is needed as existing data indicate that
EoE-related costs are striking and consistently higher than
those of healthy consumers (10, 47). The economic impact of
poorly coordinated care encompassing the possible duplication
of services as parents attempt to meet the healthcare needs of
their family must be carefully considered. Collaboration between
healthcare practitioners is thus even more important as it can
help to identify the areas of unnecessary expenditure for patients
and reduce financial barriers to treatment.
There are several study limitations. Only respondents
involving a child diagnosed with EoE who had undergone
an endoscopy were included in the analysis. An endoscopy
is predominantly performed by a pediatric gastroenterologist;
however, not all respondents indicated that their child had
seen a pediatric gastroenterologist (or other medical doctor)
for their EoE. This may be reflective of some respondents
including only consultations post-EoE diagnosis and results
in perceived lower numbers of pediatric gastroenterologist
and other practitioner consultations as they occurred prior
to or during the diagnosis process. Additionally, as the
question regarding practitioner use ever required respondents
to indicate agreement and no other option was provided,
missing answers were classified as “no.” Therefore, practitioner
visits may be under-reported due to missing answers. This
study was based on self-reports and may therefore be
subject to recall bias. Questions surrounding the efficacy
of medications and therapies are perceptions of the carer
only and may not be a true reflection of histological
change in EoE.
CONCLUSIONS
This study identified a large variety of practitioners who are
involved in the care of EoE patients, resulting in a diverse
range of treatment options being recommended and accessed
and in a possible treatment-related burden. In addition, carer
involvement in the choice of treatment for pediatric EoE is
high. Referrals and collaboration between healthcare providers
as well as education and shared decision making with carers
are required to successfully navigate this complex disease and
provide adequate care for children with EoE. The high rate of
CM use, particularly given the absence of EoE guidelines in
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Australia, warrants further attention by clinicians, policy makers,
and researchers.
DATA AVAILABILITY STATEMENT
The research data are stored securely as per Griffith University
ethics approval and cannot be made publicly available. The
authors will consider any reasonable request for access to the
anonymized data according to the privacy statement provided
with information and consent materials. Please direct any
requests to the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Griffith University Human Research
Ethics Committee (#2018/120). The patients/participants
provided their written informed consent to participate in
this study.
AUTHOR CONTRIBUTIONS
NH drafted the manuscript. All authors contributed to the
study design, data analysis, and interpretation, provided editorial
comments, read, and approved the final manuscript.
ACKNOWLEDGMENTS
We would like to thank the following people: all survey
participants, AusEE Inc. and members, Sarah Gray, the AusEE
medical advisory board, Allergy and Anaphylaxis Australia,
Allergy and Immunology Foundation of Australasia, Rare Voices
Australia, My Food Allergy Friends, specialist doctors related
to EoE management, general practitioners, and hospital-based
pediatric allergy and gastroenterology departments across
Australia, ASCIA, the Gastroenterological Society of
Australia, Australian Society of Pediatric Gastroenterology
Hepatology and Nutrition, and the Royal Australian College of
General Practitioners.
REFERENCES
1. Chawla N, Deshmukh M, Sharma A, Patole S. Strategies for medical
management of pediatric eosinophilic esophagitis. J Pediatr Gastroenterol
Nutr. (2016) 63:336–9. doi: 10.1097/MPG.0000000000001298
2. Australasian Society of Clinical Immunology and Allergy. Eosinophilic
Oesophagitis. Available online at: https://www.allergy.org.au/patients/food-
other-adverse-reactions/eosinophilic-oesophagitis (accessed July 16, 2019).
3. Dellon ES, Erichsen R, Baron JA, Shaheen NJ, Vyberg M, Sorensen HT,
et al. The increasing incidence and prevalence of eosinophilic esophagitis
outpaces changes in endoscopic and biopsy practice: national population-
based estimates from Denmark. Aliment Pharmacol Ther. (2015) 41:662–70.
doi: 10.1111/apt.13129
4. Moawad FJ. Eosinophilic esophagitis: incidence and prevalence. Gastrointest
Endosc Clin N Am. (2018) 28:15–25. doi: 10.1016/j.giec.2017.07.001
5. Lucendo AJ, Molina-Infante J, Arias Á, von Arnim U, Bredenoord AJ,
Bussmann C, et al. Guidelines on eosinophilic esophagitis: evidence-
based statements and recommendations for diagnosis and management
in children and adults. U Eur Gastroenterol J. (2017) 5:335–58.
doi: 10.1177/2050640616689525
6. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA.
ACG clinical guideline: evidenced based approach to the diagnosis and
management of esophageal eosinophilia and eosinophilic esophagitis (EoE).
Am J Gastroenterol. (2013) 108:679–92. doi: 10.1038/ajg.2013.71
7. Gómez-Aldana A, Jaramillo-Santos M, Delgado A, Jaramillo C,
Lúquez-Mindiola A. Eosinophilic esophagitis: current concepts in
diagnosis and treatment. World J Gastroenterol. (2019) 25:4598–613.
doi: 10.3748/wjg.v25.i32.4598
8. Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit
N, et al. Updated international consensus diagnostic criteria for eosinophilic
esophagitis: proceedings of the agree conference. Gastroenterology. (2018)
155:1022–33. doi: 10.1053/j.gastro.2018.07.009
9. Yaxley JP, Chakravarty B. Eosinophilic oesophagitis: a guide for primary care.
Aust Fam Physician. (2015) 44:723–27.
10. Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care
utilization, costs, and the burden of disease related to eosinophilic
esophagitis in the United States. Am J Gastroenterol. (2015) 110:626–32.
doi: 10.1038/ajg.2014.316
11. National Library of Medicine. Collection Development Guidelines of the
National Library of Medicine [Internet]. Bethesda, MD: National Library of
Medicine. Complementary and Alternative Medicine (2019).
12. Wadhera V. Complementary and alternative medicine in children
attending gastroenterology clinics: usage patterns and reasons for use. J
Paediatr Child Health. (2011) 47:904–10. doi: 10.1111/j.1440-1754.2011.02
100.x
13. Adams D, Schiffgen M, Kundu A, Dagenais S, Clifford T,
Baydala L, et al. Patterns of utilization of complementary and
alternative medicine in 2 pediatric gastroenterology clinics. J Pediatr
Gastroenterol Nutr. (2014) 59:334–39. doi: 10.1097/MPG.00000000000
00439
14. Foley H, Steel A, Cramer H, Wardle J, Adams J. Disclosure of complementary
medicine use to medical providers: a systematic review and meta-analysis. Sci
Rep. (2019) 9:1573. doi: 10.1038/s41598-018-38279-8
15. Pike A, Etchegary H, Godwin M, McCrate F, Crellin J, Mathews M, et al.
Use of natural health products in children: qualitative analysis of parents’
experiences. Can Fam Physician. (2013) 59:e372–8.
16. Bakas T. Bakas caregiving outcomes scale. In: Michalos AC, editor.
Encyclopedia of Quality of Life and Well-Being Research. Dordrecht:
Springer Netherlands (2014). p. 319–21. doi: 10.1007/978-94-007-075
3-5_143
17. Franciosi JP, Hommel KA, Greenberg AB, DeBrosse CW, Greenler AJ, Abonia
JP, et al. Development of the pediatric quality of life inventoryTM eosinophilic
esophagitis module items: qualitative methods. BMC Gastroenterol. (2012)
12:135. doi: 10.1186/1471-230X-12-135
18. Varni JW, Limbers CA, Neighbors K, Schulz K, Lieu JEC, Heffer RW,
et al. The PedsQLTM infant scales: feasibility, internal consistency reliability,
and validity in healthy and ill infants. Qual Life Res. (2011) 20:45–55.
doi: 10.1007/s11136-010-9730-5
19. Australian Bureau of Statistics. 2016 Census Household Form. Available
online at: www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main
%20Features802016/\protect\T1\textdollarFILE/2016%20Census%20Sample
%20Household%20Form.pdf (accessed September 12, 2017).
20. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity
of the pediatric quality of life inventory version 4.0 generic core
scales in healthy and patient populations. Med care. (2001) 39:800–12.
doi: 10.1097/00005650-200108000-00006
21. Harnett JE, McIntyre E, Steel A, Foley H, Sibbritt D, Adams J. Use
of complementary medicine products: a nationally representative cross-
sectional survey of 2019 Australian adults. BMJ Open. (2019) 9:e024198.
doi: 10.1136/bmjopen-2018-024198
22. Steel A, McIntyre E, Harnett J, Foley H, Adams J, Sibbritt D, et al.
Complementary medicine use in the Australian population: results of a
Frontiers in Pediatrics | www.frontiersin.org 10 April 2020 | Volume 8 | Article 147
Hannan et al. Pediatric EoE Health Service Use
nationally-representative cross-sectional survey. Sci Rep. (2018) 8:17325–25.
doi: 10.1038/s41598-018-35508-y
23. Adams D, Dagenais S, Clifford T, Baydala L, King WJ, Hervas-Malo M,
et al. Complementary and alternative medicine use by pediatric specialty
outpatients. Pediatrics. (2013) 131:225–32. doi: 10.1542/peds.2012-1220
24. Busato A, Künzi B. Differences in the quality of interpersonal care in
complementary and conventional medicine. BMC Comple Altern Med. (2010)
10:63. doi: 10.1186/1472-6882-10-63
25. Doering JH, Reuner G, Kadish NE, Pietz J, Schubert-Bast S. Pattern
and predictors of complementary and alternative medicine (CAM) use
among pediatric patients with epilepsy. Epilepsy Behav. (2013) 29:41–6.
doi: 10.1016/j.yebeh.2013.06.025
26. Dolceamore TR, Altomare F, Zurlo F, Miniero R. Use of alternative-
complementary-medicine (CAM) in Calabrian children. Ital J Pediatr. (2012)
38:70. doi: 10.1186/1824-7288-38-70
27. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ,
Abonia JP, et al. Quality of life in pediatric eosinophilic oesophagitis:
what is important to patients?. Child Care Health Dev. (2012) 38:477–83.
doi: 10.1111/j.1365-2214.2011.01265.x
28. Gottschling S, Gronwald B, Schmitt S, Schmitt C, Langler A, Leidig E, et al. Use
of complementary and alternative medicine in healthy children and children
with chronic medical conditions in Germany. Comple Ther Med. (2013) 21
(Suppl. 1):S61–9. doi: 10.1016/j.ctim.2011.06.001
29. Birdee GS, Phillips RS, Davis RB, Gardiner P. Factors associated with pediatric
use of complementary and alternative medicine. Pediatrics. (2010) 125:249–
56. doi: 10.1542/peds.2009-1406
30. Harris RF, Menard-Katcher C, Atkins D, Furuta GT, Klinnert
MD. Psychosocial dysfunction in children and adolescents with
eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. (2013) 57:500–05.
doi: 10.1097/MPG.0b013e31829ce5ad
31. Klinnert MD, Silveira L, Harris R, Moore W, Atkins D, Fleischer DM,
et al. Health-related quality of life over time in children with eosinophilic
esophagitis and their families. J Pediatr Gastroenterol Nutr. (2014) 59:308–16.
doi: 10.1097/MPG.0000000000000451
32. Lindberg A, Fossum B, Karlen P, Oxelmark L. Experiences of complementary
and alternative medicine in patients with inflammatory bowel disease
- a qualitative study. BMC Comple Altern Med. (2014) 14:407–07.
doi: 10.1186/1472-6882-14-407
33. Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I, et al. Inflammatory
bowel disease: a patient’s and caregiver’s perspective. Dig Dis Sci. (2009)
54:2671–79. doi: 10.1007/s10620-008-0658-3
34. Manderson L, Canaway R. Serious decisions: chronic conditions
and choice of provider. Qual Health Res. (2013) 23:1638–48.
doi: 10.1177/1049732313508475
35. Nousiainen P, Merras-Salmio L, Aalto K, Kolho K-L. Complementary and
alternative medicine use in adolescents with inflammatory bowel disease and
juvenile idiopathic arthritis. BMC Comple Altern Med. (2014) 14:124–24.
doi: 10.1186/1472-6882-14-124
36. Sadlo A, Altevers J, Peplies J, Kaltz B, Claßen M, Bauer A, et al. Measuring
satisfaction with health care in young persons with inflammatory bowel
disease -an instrument development and validation study. BMC Health Serv
Res. (2014) 14:97. doi: 10.1186/1472-6963-14-97
37. Taft TH, Kern E, Keefer L, Burstein D, Hirano I. Qualitative assessment
of patient-reported outcomes in adults with eosinophilic esophagitis.
J Clin Gastroenterol. (2011) 45:769–74. doi: 10.1097/MCG.0b013e3182
166a5a
38. Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR,
et al. Building a measurement framework of burden of treatment in complex
patients with chronic conditions: a qualitative study. Patient Relat Outcome
Meas. (2012) 3:39–49. doi: 10.2147/PROM.S34681
39. Australian Government Department of Health. The Australian Health System.
Available online at: https://www.health.gov.au/health-topics/medicare
(accessed February 16, 2020).
40. Australian Government Department of Health. Private Health Insurance.
Available online at: https://www.health.gov.au/health-topics/private-
health-insurance?utm_source=health.gov.au&utm_medium=redirect&utm_
campaign=digital_transformation&utm_content=private-health-insurance
(accessed August 24, 2019).
41. Australian Government Department of Human Services. Carer
Allowance. Available online at: https://www.humanservices.gov.au/
individuals/services/centrelink/carer-allowance (accessed August
24, 2019).
42. Australian Government Department of Human Services. Concession and
Health Care Cards. Available online at: https://www.humanservices.gov.au/
individuals/subjects/concession-and-health-care-cards (accessed August 24,
2019).
43. Cherian S, Smith NM, Forbes DA. Rapidly increasing prevalence of
eosinophilic oesophagitis in Western Australia. Arch Dis Child. (2006)
91:1000–04. doi: 10.1136/adc.2006.100974
44. Australian Government Federal Register of Legislation. Therapeutic Goods
Regulations 1990. Available online at: https://www.legislation.gov.au/Details/
F2013C00670.
45. Dellon ES, Hirano I. Epidemiology and natural history of
eosinophilic esophagitis. Gastroenterology. (2018) 154:319–32.e3.
doi: 10.1053/j.gastro.2017.06.067
46. Australian Bureau of Statistics. 2016 Census QuickStats. Available online at:
https://quickstats.censusdata.abs.gov.au/census_services/getproduct/census/
2016/quickstat/036 (accessed February 13, 2019).
47. Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen
NJ. Health-related quality of life and costs associated with eosinophilic
esophagitis: a systematic review. Clin Gastroenterol Hepatol. (2018) 16:495–
503. doi: 10.1016/j.cgh.2017.06.036
48. Krishnan UK, McLennan LM, Li Chan JC, Clarkson CC, Menzies JM,
Hughes JH, et al. P-23: quality of life in children with eosinophilic
esophagitis associated with esophageal atresia and tracheoesophageal fistula.
Dis Esophagus. (2016) 29:294–95. doi: 10.1093/dote/29.3.294d
49. Menard-Katcher P, Marks KL, Liacouras CA, Spergel JM, Yang Y-X, Falk
GW. The natural history of eosinophilic oesophagitis in the transition
from childhood to adulthood. Aliment Pharm Ther. (2013) 37:114–21.
doi: 10.1111/apt.12119
50. Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk
GW. Natural history of eosinophilic esophagitis: a systematic review
of epidemiology and disease course. Dis Esophagus. (2018) 31:1–14.
doi: 10.1093/dote/doy015
51. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use
of proton pump inhibitors: expert review and best practice advice from the
american gastroenterological association. Gastroenterology. (2017) 152:706–
15. doi: 10.1053/j.gastro.2017.01.031
52. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A,
Echeverría L, Borrell B, et al. Long-term treatment with proton pump
inhibitors is effective in children with eosinophilic esophagitis. J Pediatr
Gastroenterol Nutr. (2018) 67:210–16. doi: 10.1097/MPG.0000000000001952
53. Yakoob MY, Lo CW. Nutrition (Micronutrients) in child growth and
development: a systematic review on current evidence, recommendations and
opportunities for further research. J Dev Behav Pediatr. (2017) 38:665–79.
doi: 10.1097/DBP.0000000000000482
54. Serpico MR, Boyle BM, Kemper KJ, Kim SC. Complementary and
alternative medicine use in children with inflammatory bowel diseases:
a single-center survey. J Pediatr Gastroenterol Nutr. (2016) 63:651–57.
doi: 10.1097/MPG.0000000000001187
55. Zhan T, Ali A, Choi JG, Lee M, Leung J, Dellon ES, et al. Model
to determine the optimal dietary elimination strategy for treatment of
eosinophilic esophagitis. Clin Gastroenterol Hepatol. (2018) 16:1730–37.e2.
doi: 10.1016/j.cgh.2018.04.013
56. Ursino MG, Poluzzi E, Caramella C, De Ponti F. Excipients in medicinal
products used in gastroenterology as a possible cause of side effects.
Regul Toxicol Pharmacol. (2011) 60:93–105. doi: 10.1016/j.yrtph.2011.
02.010
57. Pavli F, Tassou C, Nychas GE, Chorianopoulos N. Probiotic incorporation in
edible films and coatings: bioactive solution for functional foods. Int J Mol Sci.
(2018) 19:150. doi: 10.3390/ijms19010150
58. Aarthun A, Akerjordet K. Parent participation in decision-making in health-
care services for children: an integrative review. J Nurs Manag. (2014) 22:177–
91. doi: 10.1111/j.1365-2834.2012.01457.x
59. Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP,
et al. Alignment of parent- and child-reported outcomes and histology in
Frontiers in Pediatrics | www.frontiersin.org 11 April 2020 | Volume 8 | Article 147
Hannan et al. Pediatric EoE Health Service Use
eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol
Pract. (2018) 142:130–38.e1. doi: 10.1016/j.jaci.2018.05.014
60. Edbrooke-Childs J, Jacob J, Argent R, Patalay P, Deighton J, Wolpert M.
The relationship between child- and parent-reported shared decision making
and child-, parent-, and clinician-reported treatment outcome in routinely
collected child mental health services data. Clin Child Psychol Psychiatry.
(2016) 21:324–38. doi: 10.1177/1359104515591226
61. Cotton CC, Durban R, Dellon ES. Illuminating elimination
diets: controversies regarding dietary treatment of eosinophilic
esophagitis. Dig Dis Sci. (2019) 64:1401–08. doi: 10.1007/s10620-019-
05602-w
62. Steinbach EC, Hernandez M, Dellon ES. Eosinophilic esophagitis
and the eosinophilic gastrointestinal diseases: approach to diagnosis
and management. J Allergy Clin Immunol Pract. (2018) 6:1483–95.
doi: 10.1016/j.jaip.2018.06.012
63. Australian Health Practitioner Regulation Agency (AHPRA). Professions
& Divisions. Available online at: https://www.ahpra.gov.au/Registration/
Registers-of-Practitioners/Professions-and-Divisions.aspx (accessed
February 16, 2020).
64. Chang JW, Saini SD, Mellinger JL, Chen JW, Zikmund-Fisher BJ,
Rubenstein JH. Management of eosinophilic esophagitis is often
discordant with guidelines and not patient-centered: results of a survey
of gastroenterologists. Dis Esophagus. (2019) 32:1–6. doi: 10.1093/dote/
doy133
65. Anderson M, Elliott EJ, Zurynski YA. Australian families living
with rare disease: experiences of diagnosis, health services use and
needs for psychosocial support. Orphanet J Rare Dis. (2013) 8:1–9.
doi: 10.1186/1750-1172-8-22
66. Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? parents of children with
rare diseases’ experiences of navigating the healthcare system. J Genet Couns.
(2018) 28:80–90. doi: 10.1007/s10897-018-0294-9
67. Australian Prudential Regulation Authority (APRA). Quarterly




Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Hannan, Steel, McMillan and Tiralongo. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pediatrics | www.frontiersin.org 12 April 2020 | Volume 8 | Article 147
